|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fleshner N: Defining high-risk prostate
cancer: Current status. Can J Urol. 12(Suppl 1): S14–S17;
discussion 94–96. 2005.
|
|
3
|
Hotte SJ and Saad F: Current management of
castrate-resistant prostate cancer. Curr Oncol. 17(Suppl 2):
S72–S79. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Qu S, Wang K, Xue H and Wang Y, Wu R, Liu
C, Gao AC, Gout PW, Collins CC and Wang Y: Enhanced anticancer
activity of a combination of docetaxel and Aneustat (OMN54) in a
patient-derived, advanced prostate cancer tissue xenograft model.
Mol Oncol. 8:311–322. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Olsson A, Björk A, Vallon-Christersson J,
Isaacs JT and Leanderson T: Tasquinimod (ABR-215050), a
quinoline-3-carboxamide anti-angiogenic agent, modulates the
expression of thrombospondin-1 in human prostate tumors. Mol
Cancer. 9:1072010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xing N, Chen Y, Mitchell SH and Young CY:
Quercetin inhibits the expression and function of the androgen
receptor in LNCaP prostate cancer cells. Carcinogenesis.
22:409–414. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang F, Song L, Wang H, Wang J, Xu Z and
Xing N: Quercetin in prostate cancer: Chemotherapeutic and
chemopreventive effects, mechanisms and clinical application
potential (Review). Oncol Rep. 33:2659–2668. 2015.PubMed/NCBI
|
|
8
|
Yang F, Song L, Wang H, Wang J, Xu Z and
Xing N: Combination of quercetin and 2-methoxyestradiol enhances
inhibition of human prostate cancer LNCaP and PC-3 cells xenograft
tumor growth. PLoS One. 10:e01282772015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shi X, Deepak V, Wang L, Ba X, Komori T,
Zeng X and Liu W: Thrombospondin-1 is a putative target gene of
Runx2 and Runx3. Int J Mol Sci. 14:14321–14332. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen Y, Li XX, Xing NZ and Cao XG:
Quercetin inhibits choroidal and retinal angiogenesis in vitro.
Graefes Arch Clin Exp Ophthalmol. 246:373–378. 2008. View Article : Google Scholar
|
|
11
|
Wang G, Song L, Wang H and Xing N:
Quercetin synergizes with 2-methoxyestradiol inhibiting cell growth
and inducing apoptosis in human prostate cancer cells. Oncol Rep.
30:357–363. 2013.PubMed/NCBI
|
|
12
|
Sharmila G, Bhat FA, Arunkumar R, Elumalai
P, Raja Singh P, Senthilkumar K and Arunakaran J: Chemopreventive
effect of quercetin, a natural dietary flavonoid on prostate cancer
in in vivo model. Clin Nutr. 33:718–726. 2014. View Article : Google Scholar
|
|
13
|
Reiner T, de las Pozas A, Gomez LA and
Perez-Stable C: Low dose combinations of 2-methoxyestradiol and
docetaxel block prostate cancer cells in mitosis and increase
apoptosis. Cancer Lett. 276:21–31. 2009. View Article : Google Scholar
|
|
14
|
Ma ZS, Huynh TH, Ng CP, Do PT, Nguyen TH
and Huynh H: Reduction of CWR22 prostate tumor xenograft growth by
combined tamoxifen-quercetin treatment is associated with
inhibition of angiogenesis and cellular proliferation. Int J Oncol.
24:1297–1304. 2004.PubMed/NCBI
|
|
15
|
Ma Z, Hung Nguyen T, Hoa Huynh T, Tien Do
P and Huynh H: Reduction of rat prostate weight by combined
quercetin-finasteride treatment is associated with cell cycle
deregulation. J Endocrinol. 181:493–507. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Borghetti GS, Lula IS, Sinisterra RD and
Bassani VL: Quercetin/beta-cyclodextrin solid complexes prepared in
aqueous solution followed by spray-drying or by physical mixture.
AAPS PharmSciTech. 10:235–242. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Utesch D, Feige K, Dasenbrock J, Broschard
TH, Harwood M, Danielewska-Nikiel B and Lines TC: Evaluation of the
potential in vivo genotoxicity of quercetin. Mutat Res. 654:38–44.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cialdella-Kam L, Nieman DC, Sha W, Meaney
MP, Knab AM and Shanely RA: Dose-response to 3 months of
quercetin-containing supplements on metabolite and quercetin
conjugate profile in adults. Br J Nutr. 109:1923–1933. 2013.
View Article : Google Scholar
|
|
19
|
Shoskes DA, Zeitlin SI, Shahed A and
Rajfer J: Quercetin in men with category III chronic prostatitis: A
preliminary prospective, double-blind, placebo-controlled trial.
Urology. 54:960–963. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ren B, Yee KO, Lawler J and Khosravi-Far
R: Regulation of tumor angiogenesis by thrombospondin-1. Biochim
Biophys Acta. 1765:178–188. 2006.PubMed/NCBI
|
|
21
|
Hanahan D and Folkman J: Patterns and
emerging mechanisms of the angiogenic switch during tumorigenesis.
Cell. 86:353–364. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee DH and Lee YJ: Quercetin suppresses
hypoxia-induced accumulation of hypoxia-inducible factor-1alpha
(HIF-1alpha) through inhibiting protein synthesis. J Cell Biochem.
105:546–553. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pratheeshkumar P, Budhraja A, Son YO, Wang
X, Zhang Z, Ding S, Wang L, Hitron A, Lee JC, Xu M, et al:
Quercetin inhibits angiogenesis mediated human prostate tumor
growth by targeting VEGFR-2 regulated AKT/mTOR/P70S6K signaling
pathways. PLoS One. 7:e475162012. View Article : Google Scholar
|
|
24
|
Miyata Y and Sakai H: Thrombospondin-1 in
urological cancer: Pathological role, clinical significance, and
therapeutic prospects. Int J Mol Sci. 14:12249–12272. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kazerounian S, Yee KO and Lawler J:
Thrombospondins in cancer. Cell Mol Life Sci. 65:700–712. 2008.
View Article : Google Scholar : PubMed/NCBI
|
